NAARDEN, The Netherlands & MUNICH, Germany-(BUSINESS WIRE)-Forbion Capital Partners, a leading investment firm dedicated to the life science sector, today announces the final closings of both FCF I Co-Invest Fund and of FCF II, raising a total of more than ¬190m ($240m). (…)
[Read article]
[Source: Business Wire]
Press Release - Exosome Diagnostics, Inc., http:/www.ExosomeDX.com, the developer of minimally-invasive molecular diagnostics, today announced that it has raised $20 million co-led by NGN Capital (www.ngncapital.com, ( NGN ) New York, and Forbion Capital Partners (…)
[Read article]
[Source: BioSpace]
MALVERN, Pa.-(BUSINESS WIRE)-Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat inflammatory and fibrotic diseases, today announced that it has raised $12 million in a Series C financing round. Forbion Capital Partners led the round, (…)
[Read article]
[Source: BioSpace]
OBJECTIVE: MMP-13 is highly upregulated in arthritis and therefore strongly implicated in the pathogenesis of osteoarthritis (OA). Selective inhibition of MMP-13 may provide the desired cartilage degradation protection, while overcoming the musculoskeletal toxicity seen with (…)
[Read article]
[Source: NCBI PubMed]
Third Quarter 2009 Revenue Decreased 2 Percent to $3.8 BillionThird Quarter 2009 GAAP Earnings Per Share Increased 30 Percent to $1.36Reaffirmed 2009 Total Revenue Trending Towards Upper End of Current Guidance Range of $14.4-$14.8 Billion2009 Adjusted Earnings Per Share (…)
[Read article]
[Source: PR Newswire]
18.06.2009 - According to Frost & Sullivan, the pharmaceutical industry had witnessed a huge wave of mergers and acquisitions activities in the past decade. Recently, there has been a surge in M&A activities, especially mega-M&As. Clearly, the current economic downturn, (…)
[Read article]
[Source: Bionity.com]
UTRECHT, Netherlands & CAMBRIDGE, England-(BUSINESS WIRE)-PanGenetics, an antibody development company which is developing PG110, a humanized antibody to Nerve Growth Factor (NGF), today announced it has entered into an agreement with Abbott (NYSE: ABT) under which Abbott (…)
[Read article]
[Source: Business Wire]
ROTTERDAM, The Netherlands, September 10 /PRNewswire/ - arGEN-X BV, a biopharmaceutical company focused on the discovery and development of human antibodies using its proprietary SIMPLE Antibody(TM) platform, today announced the successful first closing of its Series A equity (…)
[Read article]
[Source: PR Newswire]
Second Quarter 2009 Revenue Decreased 1 Percent to $3.7 BillionSecond Quarter 2009 GAAP Earnings Per Share Increased 49 Percent to $1.252009 Total Revenue Trending Towards Upper End of Current Guidance Range of $14.4-$14.8 Billion2009 Adjusted Earnings Per Share Guidance Range (…)
[Read article]
[Source: PR Newswire]
NEW YORK-(BUSINESS WIRE)-Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Amgen Inc.: PharmaVitae Profile http:/www.reportlinker.com/p0132995/Reportlinker-Adds-Amgen-Inc-PharmaVitae-Profile.html Introduction This (…)
[Read article]
[Source: Business Wire]
NEW YORK-(BUSINESS WIRE)-Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Prescription Drugs http:/www.reportlinker.com/p0131233/Reportlinker-Adds-Prescription-Drugs.html This report analyzes the worldwide markets (…)
[Read article]
[Source: Business Wire]
OBJECTIVE: Matrix metalloproteinases (MMPs) have long been considered excellent targets for osteoarthritis (OA) treatment. However, clinical utility of broad-spectrum MMP inhibitors developed for this purpose has been restricted by dose-limiting musculoskeletal side effects (…)
[Read article]
[Source: NCBI PubMed]
CAMBRIDGE, Mass.-(BUSINESS WIRE)-Zafgen, Inc., a private venture-backed biopharmaceutical company focused on developing novel obesity therapeutics, today announced the appointment of Matthias Jaffe to chief financial officer and vice president of business development. Mr. (…)
[Read article]
[Source: Business Wire]
First Quarter 2009 Revenue Decreased 8 Percent to $3.3 Billion First Quarter 2009 GAAP Earnings Per Share Decreased 3 Percent to $0.98 2009 Total Revenue Guidance Range Lowered from $14.8 to $15.2 Billion to $14.4 to $14.8 Billion 2009 Adjusted Earnings Per Share Guidance Range (…)
[Read article]
[Source: PR Newswire]
The mode of binding and the activity of the first two non-zinc chelating, potent, and selective inhibitors of human neutrophil collagenase are reported. The crystal structures of the catalytic domain of MMP-8, respectively complexed with each inhibitor, reveals that both (…)
[Read article]
[Source: NCBI PubMed]
Full Year 2008 Revenue Increased 2 Percent to $15.0 Billion; Fourth Quarter 2008 Revenue Flat at $3.75 BillionFull Year 2008 GAAP Earnings Per Share Increased 38 Percent to $3.90; Fourth Quarter 2008 GAAP Earnings Per Share Increased 20 Percent to $0.912009 Total Revenue (…)
[Read article]
[Source: BioSpace]
Full Year 2008 Revenue Increased 2 Percent to $15.0 Billion; Fourth Quarter 2008 Revenue Flat at $3.75 Billion Full Year 2008 GAAP Earnings Per Share Increased 38 Percent to $3.90; Fourth Quarter 2008 GAAP Earnings Per Share Increased 20 Percent to $0.91 2009 Total Revenue (…)
[Read article]
[Source: PR Newswire]
DUBLIN, Ireland-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/e755a8/valueadded_pharma) has announced the addition of Decision Resources, Inc.'s new report "Value-Added Pharma: How to Accomplish the Impossible" to their offering. The pharma (…)
[Read article]
[Source: Business Wire]
THOUSAND OAKS, Calif., Oct. 22 /PRNewswire-FirstCall/ - Amgen reported adjusted earnings per share (EPS), excluding stock option expense and certain other expenses, of $1.23 for the third quarter of 2008, an increase of 14 percent compared to $1.08 for the third quarter of (…)
[Read article]
[Source: BioSpace]
Third Quarter 2008 Revenue Increased 7 Percent to $3.9 Billion Third Quarter 2008 GAAP Earnings Per Share were $1.09, an Increase from Third Quarter 2007 GAAP Earnings Per Share of $0.18 Full Year Revenue Guidance Raised from $14.6 Billion - $14.9 Billion to $14.9 Billion - (…)
[Read article]
[Source: PR Newswire]
BOSTON, Oct. 14 /PRNewswire/ - Surface Logix, a privately held biopharmaceutical company focused on using biophysical chemistry to create and develop novel small molecule drugs, is pleased to announce the appointment of Keith Dionne, Ph.D. to the position of President and (…)
[Read article]
[Source: PR Newswire]
DUBLIN, Ireland-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/121eac/evolving_trends_in) has announced the addition of Decision Resources, Inc.'s new report "Evolving Trends in Licensing: Strategies for Building and Retaining Value in (…)
[Read article]
[Source: Business Wire]
DUBLIN, Ireland-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/ad445d/dealmaking_and_fin) has announced the addition of Decision Resources, Inc.'s new report "Dealmaking and Financing: Mergers and Acquisitions in Key Markets" to their (…)
[Read article]
[Source: Business Wire]
THOUSAND OAKS, Calif.-(BUSINESS WIRE)-Amgen (NASDAQ:AMGN) reported adjusted earnings per share (EPS), excluding stock option expense and certain other expenses, of $1.14 for the second quarter of 2008, an increase of 2 percent compared to $1.12 for the second quarter of 2007. (…)
[Read article]
[Source: Business Wire]
BOSTON-(BUSINESS WIRE)-Halloran Consulting Group (HCG), specialists in clinical operations management for established and emerging life sciences companies, today announced key appointments to the executive team and a restructuring of its practice areas as a result of new (…)
[Read article]
[Source: Business Wire]
NEW YORK-(BUSINESS WIRE)-Reportlinker.com announces that a new market research report related to the Cardiovascular diseases industry is available in its catalogue. The World Diabetes Market, 2006-2025 To order this report: (…)
[Read article]
[Source: Business Wire]
Paclitaxel and related taxanes exhibit their anticancer activity by promoting tubulin polymerization and stabilizing microtubules, which results in mitotic G2/M arrest and apoptosis. The clinical success of paclitaxel in treating a wide array of tumor types has led to numerous (…)
[Read article]
[Source: NCBI PubMed]
THOUSAND OAKS, Calif.-(BUSINESS WIRE)-Amgen (NASDAQ:AMGN) reported adjusted EPS, excluding stock option expense and certain other expenses, of $1.00 in the fourth quarter of 2007, an increase of 11 percent compared to $0.90 in the fourth quarter of 2006. Adjusted net income, (…)
[Read article]
[Source: Business Wire]
THOUSAND OAKS, Calif.-(BUSINESS WIRE)-Amgen (NASDAQ:AMGN) Chairman and Chief Executive Officer Kevin Sharer in a presentation to investors at today s JP Morgan Healthcare Conference, said that, despite regulatory and reimbursement changes affecting sales of Erythropoiesis (…)
[Read article]
[Source: Business Wire]
THOUSAND OAKS, Calif.-(BUSINESS WIRE)-Amgen (NASDAQ:AMGN) reported adjusted earnings per share (EPS), excluding stock option expense and certain other expenses, of $1.08 for the third quarter of 2007, an increase of 4 percent compared to $1.04 for the third quarter of 2006. (…)
[Read article]
[Source: Business Wire]
THOUSAND OAKS, Calif.-(BUSINESS WIRE)-Amgen (NASDAQ: AMGN) today announced initiatives that will reduce company staff by 12-14 percent and deliver other operational efficiencies while ensuring continued investment at industry-leading levels in research and development. These (…)
[Read article]
[Source: Business Wire]
THOUSAND OAKS, Calif.-(BUSINESS WIRE)-Amgen (NASDAQ: AMGN) reported adjusted earnings per share (EPS), excluding stock option expense and certain other expenses, of $1.12 for the second quarter of 2007, an increase of 7 percent compared to $1.05 during the second quarter of (…)
[Read article]
[Source: Business Wire]
THOUSAND OAKS, Calif.-(BUSINESS WIRE)-Amgen (NASDAQ:AMGN) today announced the completion of its acquisition of Alantos, a private company developing drugs for the treatment of diabetes and inflammatory diseases. The transaction provides Amgen with Alantos s DPP-IV inhibitor in (…)
[Read article]
[Source: Business Wire]
THOUSAND OAKS, Calif., & CAMBRIDGE, Mass.-(BUSINESS WIRE)-Amgen (NASDAQ:AMGN) announced today that it has agreed to acquire Alantos, a private company developing drugs for the treatment of diabetes and inflammatory diseases. Alantos lead drug candidate, ALS 2-0426, is a DPP-IV (…)
[Read article]
[Source: Business Wire]
CAMBRIDGE, Mass.-(BUSINESS WIRE)-Dyax Corp. (Nasdaq: DYAX) announced today that Gustav A. Christensen is joining the Company as Executive Vice President and Chief Business Officer. Mr. Christensen joins Dyax s executive management team where he will oversee and lead the Company (…)
[Read article]
[Source: Business Wire]
Alantos Pharmaceuticals, a privately held biopharmaceutical company based on the discovery and development of small molecule drugs with a focus on type II diabetes and Osteoarthritis/inflammation, today announced that it has initiated a Phase 1 clinical study with its first (…)
[Read article]
[Source: Medical News Today]
Alantos Pharmaceuticals, a privately held biopharmaceutical company based on the discovery and development of small molecule drugs with a focus on type II diabetes and Osteoarthritis / inflammation, today announced that it has initiated a Phase 1 clinical study with its first (…)
[Read article]
[Source: Medical News Today]
Alantos Pharmaceuticals, a privately held biopharmaceutical company based on the discovery and development of small molecule drugs with a focus on type II diabetes and Osteoarthritis/inflammation, today announced that it has initiated a Phase 1 clinical study with its first (…)
[Read article]
[Source: Medical News Today]
CAMBRIDGE, Mass., Aug. 16 /PRNewswire/ - Alantos Pharmaceuticals, a privately held biopharmaceutical company based on the discovery and development of small molecule drugs with a focus on type II diabetes and Osteoarthritis/inflammation, today announced that it has initiated a (…)
[Read article]
[Source: PR Newswire]